Cynthia Rice, JDRF chief mission strategy officer, says Medicare coverage of continuous glucose monitors (CGMs) without requiring finger sticks takes a burden off people with type 1 diabetes.
Earlier this year, Medicare implemented a rule that allows coverage of CGM/automated insulin delivery systems without requiring a finger stick. What do you think the effect of this rule change will be?
Now this is an important rule that we applaud. It helps modernize the Medicare program.
These continuous glucose monitors (CGMs) help people with type 1 diabetes achieve better glucose control. We've long advocated for private plans to cover them and for Medicare to cover them—for public and private plans to cover them. This rule takes away sort of a burdensome test, which was requiring people to show that they were taking at least 4 finger sticks a day before Medicare would allow them to have a continuous glucose monitor. And it was not rooted in science—these modern CGMs are approved by the Food and Drug Administration that you don't have to use finger sticks with them. So it was adding a burden and costs to people with diabetes.
Frankly, there are many people who are using continuous glucose monitors before they get to Medicare, and then they age into Medicare and suddenly Medicare was saying, “well, we can't let you keep using this important tool unless you start using finger sticks again.” So it was sort of an unnecessary burden, and no reason why Medicare should pay for the cost of that, so we're pleased to see that be removed.
Top 5 Most-Read Articles About Automated Insulin Delivery in 2022
December 20th 2022Content published on AJMC.com focusing on automated insulin delivery devices over the past year highlighted utilization of these devices by age, compared different types of systems, looked at barriers to uptake, and examined equity issues standing in the way of access.
Read More
Primary Care Clinicians Can Embrace CGM Implementation With Support, Study Finds
December 6th 2022Patients with diabetes may benefit from continuous glucose monitoring (CGM) as a standard of care in the primary care setting, according to a recent study that assessed clinicians’ attitudes toward prescribing these tools.
Read More
Do Automated Insulin Delivery Systems Have a Place in T2D Treatment?
November 18th 2022Although automated insulin delivery systems have gained traction in type 1 diabetes, further research is needed to determine the feasibility of using such systems for patients with type 2 diabetes.
Read More